A 65-year-old kidney transplant recipient suffering from a life-threatening, drug-resistant bacterial infection has shown rapid improvement after receiving an experimental treatment containing genetically modified, virus-based micro-weapons. The patient had developed a severe Escherichia coli infection that resisted standard antibiotics, leaving him with open abdominal wounds and a massive 0.74-liter mass growing on his bladder. Facing few remaining medical options, his doctors in California obtained approval for a "compassionate use" therapy developed by Danish biotechnology firm SNIPR Biome.
The novel therapy utilizes bacteriophages—naturally occurring viruses that target and kill specific bacteria. While bacteria originally evolved CRISPR mechanisms as an immune defense against viral attacks, genetic engineers turned the tables by equipping these phages with custom CRISPR systems that target and slice crucial bacterial DNA sequences. Known as SNIPR001, this engineered phage cocktail is capable of eradicating 90 percent of E. coli strains. Crucially, the CRISPR-armed phages can penetrate stubborn bacterial biofilms, complex protective structures that normally shield pathogens from conventional antibiotics.
Administered both intravenously and applied directly to the patient's wounds, the experimental treatment produced notable results. Within a week of starting phage therapy, the open abdominal wounds began to heal, and the bladder mass shrank by half to 0.37 liters. Researchers note that because the patient was also placed on a modified cocktail of potent medications shortly before phage administration, the dramatic recovery likely reflects a synergistic effect, in which the phages disrupted protective biofilms and enabled the drugs to act more effectively.
Although medical experts caution that clinical conclusions cannot be drawn from a single compassionate-use case, the success underscores the immense potential of synthetic biology in combating the global crisis of antimicrobial resistance. A Phase II clinical trial is currently underway in the United States to determine whether SNIPR001 can prevent bloodstream infections in vulnerable cancer patients, paving the way for broader clinical applications of precision phage therapeutics.